No Data
No Data
Mirum (MIRM) Banks on Livmarli, Overdependence a Concern
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Mirum Pharmaceuticals (MIRM) Receives a Buy From Evercore ISI
Optimistic Buy Rating for Mirum Pharmaceuticals Amidst Strong Sales Growth and Expanded LIVMARLI Label
Mirum Pharmaceuticals Price Target Raised to $66.00/Share From $62.00 by Evercore ISI Group
Mirum Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
No Data